Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study

Cancer Science

Volumn 106, Issue 7, 2015, Pages 825-832

  Xu, Jiegou ^a,b   Alexander, David B ^a   Iigo, Masaaki ^a   Hamano, Hirokazu ^c   Takahashi, Satoru ^d   Yokoyama, Takako ^e   Kato, Munehiro ^e   Usami, Ikuji ^e   Tokuyama, Takeshi ^f   Tsutsumi, Masahiro ^f   Tamura, Mouka ^g   Oguri, Tetsuya ^h   Niimi, Akio ^h   Hayashi, Yoshimitsu ⁱ   Yokoyama, Yoshifumi ⁱ   Tonegawa, Ken ⁱ   Fukamachi, Katsumi ^d   Futakuchi, Mitsuru ^d   Sakai, Yuto ^d   Suzui, Masumi ^d   Kamijima, Michihiro ^d   Hisanaga, Naomi ^j   Omori, Toyonori ^d   Nakae, Dai ^k   Hirose, Akihiko ^l   Kanno, Jun ^l   Tsuda, Hiroyuki ^a   more..

^a NAGOYA CITY UNIVERSITY   (Japan)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c MORINAGA MILK INDUSTRY CO LTD   (Japan)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e Asahi Rosai Hospital   (Japan)

^f Department of Internal Medicine Saiseikai Chuwa Hospital   (Japan)

^g National Hospital Organization Nara Medical Center   (Japan)

^h NAGOYA CITY UNIVERSITY HOSPITAL   (Japan)

ⁱ Nagoya City Koseiin Medcial Welfare Center   (Japan)

^j AICHI UNIVERSITY OF EDUCATION   (Japan)

^k TOKYO UNIVERSITY OF AGRICULTURE   (Japan)

^l NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

more..

Author keywords

Asbestos; Biological markers; Chemokine CCL3; Environmental carcinogens; Mesothelioma

Indexed keywords

ASBESTOS; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESOTHELIN; CARCINOGEN; CCL3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASBESTOSIS; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; EXPOSURE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HYDROTHORAX; LIMIT OF DETECTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIOMA CELL LINE; MIDDLE AGED; NORMAL HUMAN; PLEURA PLAQUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCORING SYSTEM; SMOKING HABIT; UPREGULATION; BLOOD; CASE CONTROL STUDY; CHEMICALLY INDUCED; ENVIRONMENTAL EXPOSURE; LUNG TUMOR; MESOTHELIOMA;

ADULT; AGED; ASBESTOS; CARCINOGENS; CASE-CONTROL STUDIES; CHEMOKINE CCL3; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84936986342     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12687     Document Type: Article

References (51)

1. Marsili D, Comba P. Asbestos case and its current implications for global health. Ann Ist Super Sanita 2013; 49: 249-51.
2. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-603.
3. Ramazzini C. Asbestos is still with us: repeat call for a universal ban. Am J Ind Med 2011; 54: 168-73.
4. Robinson BW, Creaney J, Lake R et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-6.
5. Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol Int 2006; 56: 649-54.
6. Hino O, Maeda M. Diagnostic tumor marker of asbestos-related mesothelioma. Environ Health Prev Med 2008; 13: 71-4.
7. Iwahori K, Osaki T, Serada S et al. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer 2008; 62: 45-54.
8. Scherpereel A, Grigoriu B, Conti M et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173: 1155-60.
9. Shiomi K, Hagiwara Y, Sonoue K et al. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res 2008; 14: 1431-7.
10. Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 2009; 18: 646-50.
11. Pass HI, Lott D, Lonardo F et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353: 1564-73.
12. Amati M, Tomasetti M, Mariotti L, Tarquini LM, Valentino M, Santarelli L. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat Res 2008; 655: 52-8.
13. Amati M, Tomasetti M, Scartozzi M et al. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev 2008; 17: 163-70.
14. Yasumitsu A, Tabata C, Tabata R et al. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol 2010; 5: 479-83.
15. Hirayama N, Tabata C, Tabata R et al. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir Med 2011; 105: 137-42.
16. Raiko I, Sander I, Weber DG et al. Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients. BMC Cancer 2010; 10: 242.
17. Yasuda M, Hanagiri T, Shigematsu Y et al. Identification of a tumour associated antigen in lung cancer patients with asbestos exposure. Anticancer Res 2010; 30: 2631-9.
18. Maeda R, Tabata C, Tabata R, Eguchi R, Fujimori Y, Nakano T. Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma? Antioxid Redox Signal 2011; 15: 685-9.
19. Tabata C, Terada T, Tabata R et al. Serum thioredoxin-1 as a diagnostic marker for malignant peritoneal mesothelioma. J Clin Gastroenterol 2013; 47: e7-11.
20. Watzka SB, Posch F, Pass HI et al. Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2011; 142: 384-9.
21. Leivo-Korpela S, Lehtimaki L, Nieminen R et al. Adipokine adipsin is associated with the degree of lung fibrosis in asbestos-exposed workers. Respir Med 2012; 106: 1435-40.
22. Pass HI, Levin SM, Harbut MR et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012; 367: 1417-27.
23. Rostila A, Puustinen A, Toljamo T et al. Peroxiredoxins and tropomyosins as plasma biomarkers for lung cancer and asbestos exposure. Lung Cancer 2012; 77: 450-9.
24. Santarelli L, Strafella E, Staffolani S et al. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One 2011; 6: e18232.
25. Fujii M, Fujimoto N, Hiraki A et al. Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma. Cancer Sci 2012; 103: 510-4.
26. Lehtonen H, Oksa P, Lehtimaki L et al. Increased alveolar nitric oxide concentration and high levels of leukotriene B(4) and 8-isoprostane in exhaled breath condensate in patients with asbestosis. Thorax 2007; 62: 602-7.
27. Pelclova D, Fenclova Z, Kacer P, Kuzma M, Navratil T, Lebedova J. Increased 8-isoprostane, a marker of oxidative stress in exhaled breath condensate in subjects with asbestos exposure. Ind Health 2008; 46: 484-9.
28. Chow S, Campbell C, Sandrini A, Thomas PS, Johnson AR, Yates DH. Exhaled breath condensate biomarkers in asbestos-related lung disorders. Respir Med 2009; 103: 1091-7.
29. Syslova K, Kacer P, Kuzma M et al. Rapid and easy method for monitoring oxidative stress markers in body fluids of patients with asbestos or silica-induced lung diseases. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 2477-86.
30. de Gennaro G, Dragonieri S, Longobardi F et al. Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure. Anal Bioanal Chem 2010; 398: 3043-50.
31. Lehtimaki L, Oksa P, Jarvenpaa R et al. Pulmonary inflammation in asbestos-exposed subjects with borderline parenchymal changes on HRCT. Respir Med 2010; 104: 1042-9.
32. Dragonieri S, van der Schee MP, Massaro T et al. An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls. Lung Cancer 2012; 75: 326-31.
33. Cristaudo A, Bonotti A, Simonini S, Bruno R, Foddis R. Soluble markers for diagnosis of malignant pleural mesothelioma. Biomark Med 2011; 5: 261-73.
34. Creaney J, Yeoman D, Demelker Y et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008; 3: 851-7.
35. Grigoriu BD, Chahine B, Zerimech F et al. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem 2009; 42: 1046-50.
36. Grigoriu BD, Grigoriu C, Chahine B, Gey T, Scherpereel A. Clinical utility of diagnostic markers for malignant pleural mesothelioma. Monaldi Arch Chest Dis 2009; 71: 31-8.
37. Gube M, Taeger D, Weber DG et al. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol 2011; 85: 185-92.
38. Hollevoet K, Nackaerts K, Thimpont J et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 2010; 181: 620-5.
39. Luo L, Shi HZ, Liang QL, Jiang J, Qin SM, Deng JM. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med 2010; 104: 149-56.
40. Pass HI, Wali A, Tang N et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 85: 265-72; discussion 72.
41. Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009; 136: 888-96.
42. Tomasetti M, Santarell L. Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. Cancers (Basel) 2010; 2: 523-48.
43. Comabella M, Pericot I, Goertsches R et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 2005; 158: 231-9.
44. Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma-which is best? Lung Cancer 2011; 74: 55-60.
45. Grigoriu BD, Scherpereel A, Devos P et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007; 13: 2928-35.
46. Kadota J, Mizunoe S, Mito K et al. High plasma concentrations of osteopontin in patients with interstitial pneumonia. Respir Med 2005; 99: 111-7.
47. Kariuki SN, Moore JG, Kirou KA, Crow MK, Utset TO, Niewold TB. Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun 2009; 10: 487-94.
48. Ohmori R, Momiyama Y, Taniguchi H et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003; 170: 333-7.
49. Xu J, Futakuchi M, Iigo M et al. Involvement of macrophage inflammatory protein 1alpha (MIP1alpha) in promotion of rat lung and mammary carcinogenic activity of nanoscale titanium dioxide particles administered by intra-pulmonary spraying. Carcinogenesis 2010; 31: 927-35.
50. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003; 27: 1031-51.
51. IARC. Asbestos (chrysotile, amosite, crocidolite, tremolite, actinolite, and anthophyllite). IARC Monogr Arsenic, Metals, Fibres, and Dusts 2012; 100C: 219-309.